Lv4
506 积分 2023-07-04 加入
Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial
15天前
已完结
Cyclin D as a therapeutic target in cancer
18天前
已完结
Targeting IL-6 trans-signalling: past, present and future prospects
29天前
已完结
Transcription factor networks in cellular quiescence
1个月前
已完结
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
1个月前
已完结
Cyclin D as a therapeutic target in cancer
1个月前
已完结
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer The Phase 3 EXTENTORCH Randomized Clinical Trial
2个月前
已完结
Inhibitors and PROTACs of CDK2: challenges and opportunities
2个月前
已完结
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
4个月前
已完结
Discovery of New Binders for DCAF1, an Emerging Ligase Target in the Targeted Protein Degradation Field
5个月前
已完结
皖公网安备34019202002308
